Related Experiment Video
Updated: Oct 8, 2025
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
SPOP-mutant prostate cancer: Translating fundamental biology into patient care
Tiziano Bernasocchi1, Jean-Philippe P Theurillat1
1Institute of Oncology Research, Bellinzona, TI, 6500, Switzerland; Università della Svizzera italiana (USI), Faculty of Biomedical Sciences, TI, 6900, Lugano, Switzerland.
Abstract:
Comprehensive cancer genome studies have revealed genetically-defined subtypes of prostate cancer with distinct truncal driver mutations. Because prostate cancer has been largely seen as a rather uniform disease, the clinical significance of this discovery remained largely obscure. However, recent findings imply distinct biological features and therapeutic vulnerabilities linked to specific truncal mutations. Here we review our current understanding of prostate cancers harboring recurrent point mutations in the ubiquitin ligase adaptor protein SPOP and discuss opportunities for future clinical translation. More specifically, activation of the androgen receptor (AR) signaling emerges as the key oncogenic pathway. SPOP-mutant prostate cancer patients respond to AR inhibition in various clinical settings. Molecular insights on how mutant SPOP promotes tumorigenesis may open more specific therapeutic avenues which, in combination with conventional AR-targeting agents, could improve the outcome of patients with SPOP-mutant prostate cancer.
Insights
Prostate cancer subtypes with SPOP mutations show distinct features. Targeting androgen receptor (AR) signaling offers therapeutic opportunities for these specific cancer patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Prostate cancer was historically viewed as a uniform disease.
- Recent genomic studies identified genetically-defined subtypes with distinct driver mutations.
- The clinical significance of these subtypes, particularly SPOP mutations, is increasingly recognized.
Purpose of the Study:
- To review the understanding of prostate cancer with SPOP mutations.
- To discuss the biological features and therapeutic vulnerabilities of SPOP-mutant prostate cancer.
- To explore opportunities for clinical translation of these findings.
Main Methods:
- Review of comprehensive cancer genome studies.
- Analysis of molecular insights into SPOP mutations.
- Evaluation of clinical data on SPOP-mutant prostate cancer response to therapies.
Main Results:
- SPOP mutations define a distinct subtype of prostate cancer.
- Androgen receptor (AR) signaling is a key oncogenic pathway in SPOP-mutant prostate cancer.
- Patients with SPOP-mutant prostate cancer respond to AR inhibition.
Conclusions:
- SPOP-mutant prostate cancer exhibits unique biological characteristics and therapeutic vulnerabilities.
- Targeting AR signaling is a viable clinical strategy for SPOP-mutant prostate cancer.
- Further research into mutant SPOP mechanisms may reveal novel therapeutic avenues for improved patient outcomes.
